Not logged inTargeting the dopamine receptor 2 in BRAF mutant colorectal cancer
Javadi, Arman; Forsythe, Nicholas; Refaat, Alaa; Weir, Jessica-Ann; Khawaja, Hajrah; Waugh, David; Tarapore, Rohinton; Allen, Joshua E.; Johnston, Patrick; Van Schaeybroeck, Sandra .png)
Share.png)
SaveShare Save Share Save Share Save Share Save Share Save Share Save Share Save Share Save Share Save Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)Van Cutsem, E; Dicato, M; Wils, J; Cunningham, D; Diaz-Rubio, E; Glimelius, B; Haller, D; Johnston, P; Kerr, D; Koehne, CH; Labianca, R; Minsky, B; Nordlinger, B; Roth, A; Rougier, P; Schmoll, HJ Share Save Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthaseLackey, DB; Groziak, MP; Sergeeva, M; Beryt, M; Boyer, C; Stroud, RM; Sayre, P; Park, JW; Johnston, P; Slamon, D; Shepard, HM; Pegram, M Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
